8413 related articles for article (PubMed ID: 1790141)
21. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
22. High release of tumor necrosis factor alpha, interferon gamma and interleukin-6 by adherent lymphokine-activated killer cells phenotypically derived from T cells.
Koberda J; Bergmann L; Mitrou PS; Hoelzer D
J Cancer Res Clin Oncol; 1991; 117(5):425-30. PubMed ID: 1909699
[TBL] [Abstract][Full Text] [Related]
23. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells.
Igarashi T; Wynberg J; Srinivasan R; Becknell B; McCoy JP; Takahashi Y; Suffredini DA; Linehan WM; Caligiuri MA; Childs RW
Blood; 2004 Jul; 104(1):170-7. PubMed ID: 15016654
[TBL] [Abstract][Full Text] [Related]
24. Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia.
Verfaillie C; Kay N; Miller W; McGlave P
Blood; 1990 Jul; 76(2):401-8. PubMed ID: 1695114
[TBL] [Abstract][Full Text] [Related]
25. Culture medium induced morphological changes of melanoma cells associated with change in sensitivity to lysis by lymphokine-activated killer cells.
Perng YP; Lin CC; Perng IM; Shen YC; Chuang CK; Liao SK
Cancer Biother Radiopharm; 1997 Oct; 12(5):317-31. PubMed ID: 10851482
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-7 induces differential lymphokine-activated killer cell activity against human melanoma cells, keratinocytes, and endothelial cells.
Schadendorf D; Böhm M; Möller P; Grünewald T; Czarnetzki BM
J Invest Dermatol; 1994 Jun; 102(6):838-42. PubMed ID: 8006445
[TBL] [Abstract][Full Text] [Related]
27. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
[TBL] [Abstract][Full Text] [Related]
28. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of lymphokine-activated killer cells generation in vitro by soluble factors released from mixed human tumor and peripheral blood mononuclear adherent cells culture.
Eisenthal A; Barbarsteyn E; Gitstein G; Lifschitz-Mercer B
Cancer Invest; 2006 Feb; 24(1):28-34. PubMed ID: 16466989
[TBL] [Abstract][Full Text] [Related]
30. Infiltration patterns of short- and long-term cultured A-NK and T-LAK cells following adoptive immunotherapy.
Kjaergaard J; Hokland M; Nannmark U; Hokland P; Basse P
Scand J Immunol; 1998 Jun; 47(6):532-40. PubMed ID: 9652820
[TBL] [Abstract][Full Text] [Related]
31. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism.
Gamero AM; Ussery D; Reintgen DS; Puleo CA; Djeu JY
Cancer Res; 1995 Nov; 55(21):4988-94. PubMed ID: 7585540
[TBL] [Abstract][Full Text] [Related]
32. Antitumor activity, growth, and phenotype of long-term IL-2 cultures of human NK and T lymphocytes.
Fuchshuber PR; Lotzová E; Pollock RE
Lymphokine Cytokine Res; 1991 Apr; 10(1-2):51-9. PubMed ID: 1651770
[TBL] [Abstract][Full Text] [Related]
33. Natural killer and lymphokine-activated killer cell-mediated cytotoxicity in patients with oral cancer.
Gangal SG; Tatake RJ; Krishnan N; Mukhopadhyaya R; Naik SL; Fakih AR; Rao RS
Semin Surg Oncol; 1989; 5(5):347-50. PubMed ID: 2814145
[TBL] [Abstract][Full Text] [Related]
34. Distinct phenotypic and functional characteristics of human natural killer cells obtained by rapid interleukin 2-induced adherence to plastic.
Vujanovic NL; Rabinowich H; Lee YJ; Jost L; Herberman RB; Whiteside TL
Cell Immunol; 1993 Oct; 151(1):133-57. PubMed ID: 8402925
[TBL] [Abstract][Full Text] [Related]
35. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
36. Unimpaired ability to generate adherent lymphokine-activated killer (A-LAK) cells in patients with primary or metastatic liver tumors.
Schwarz RE; Iwatsuki S; Herberman RB; Whiteside TL
Cancer Immunol Immunother; 1989; 30(5):312-6. PubMed ID: 2624925
[TBL] [Abstract][Full Text] [Related]
37. Heterogeneous binding and killing behaviour of human gamma/delta-TCR+ lymphokine-activated killer cells against K562 and Daudi cells.
Vollenweider I; Vrbka E; Fierz W; Groscurth P
Cancer Immunol Immunother; 1993 May; 36(5):331-6. PubMed ID: 8477418
[TBL] [Abstract][Full Text] [Related]
38. Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes.
Lamers HJ; Gratama JW; van Putten WL; Stoter G; Bolhuis RL
Cancer Res; 1991 May; 51(9):2324-8. PubMed ID: 2015597
[TBL] [Abstract][Full Text] [Related]
39. Lysis of allogeneic and autologous melanoma cells by IL-7-induced lymphokine-activated killer cells.
Böhm M; Möller P; Kalbfleisch U; Worm M; Czarnetzki BM; Schadendorf D
Br J Cancer; 1994 Jul; 70(1):54-9. PubMed ID: 8018541
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-2 modulates the expression of lymphocyte function-associated antigen-one (LFA-1) and p150,95 during the generation of lymphokine-activated killer (LAK) cells.
Grant AJ; Merchant RE; Hall RE
Immunology; 1989 Jan; 66(1):117-24. PubMed ID: 15493273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]